Discovery of novel acetanilide derivatives as potent and selective β3-adrenergic receptor agonists

European Journal of Medicinal Chemistry

Volumn 44, Issue 6, 2009, Pages 2533-2543

  Maruyama, Tatsuya ^a   Onda, Kenichi ^a   Hayakawa, Masahiko ^a   Matsui, Tetsuo ^a   Takasu, Toshiyuki ^a   Ohta, Mitsuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

3 Adrenergic receptor; Acetanilide; Agonist; Diabetes

Indexed keywords

4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (1 NAPHTHYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (2 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (2 METHOXYPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (2 NAPHTHYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (2 PYRIDYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (3 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (3 PYRIDYL)ACETANILIDE DIHYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (4 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (4 PYRIDYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 (INDOL 3 YL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 AMINO 2 PHENYLACETANILIDE DIHYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 HYDROXY 2 PHENYLACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2 PHENYLACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL)AMINO)ETHYL) 2,2 DIPHENYLACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (2 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (2 METHOXYPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (2 PYRAZIN 2 YL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (2 QUINOLIN 2 YL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (2 THENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (3 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (3 METHOXYPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (3 THENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (4 CHLOROPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 (4 METHOXYPHENYL)ACETANILIDE HYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 AMINO 2 PHENYLACETANILIDE DIHYDROCHLORIDE; 4' (2 ((2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO)ETHYL) 2 HYDROXY 2 PHENYLACETANILIDE HYDROCHLORIDE; 4' (2 (N BENZYL N (3 (4 BENZYLOXYPHENOXY) 2 HYDROXYPROPYL)AMINOETHYL) 2 (3 PYRIDYL)ACETANILIDE; ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN;

ACETANILIDES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRAZINES; PYRIDINES; PYRIMIDINES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64249138267     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.01.022     Document Type: Article

References (18)

1. Arch J.R., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thod V.E., Wilson C., and Wilson S. Nature 309 (1984) 163-165
2. Howe R. Drugs Future 18 (1993) 529-549
3. Emorine L.J., Marullo S., Briend-Sutren M.-M., Patey G., Tate K., Delavier-Klutchko C., and Strosberg A.D. Science 245 (1989) 1118-1121
4. Emorine L.J., Feve B., Pairault J., Briend-Sutren M.-M., Nahmias C., Marullo S., Delavier-Klutchko C., and Strosberg A.D. Am. J. Clin. Nutr. 55 (1992) 215S-218S
5. Tate K.M., Briend-Sutren M.-M., Emorine L.J., Delavier-Klutchko C., Marullo S., and Strosberg A.D. Eur. J. Biochem. 196 (1991) 357-361
6. Weber A.E. Annu. Rep. Med. Chem. 33 (1998) 193-202
7. Weyer C., Gautier J.F., and Danforth Jr. E. Diabetes Metab. 25 (1999) 11-21
8. Cantello B.C.C., and Smith S.A. Drugs Future 16 (1991) 797-800
9. Bloom J.D., and Claus T.H. Drugs Future 19 (1994) 23-26
10. Arch J.R.S., and Wilson S. Int. J. Obes. 20 (1996) 191-199
11. Lipworth B.J. Br. J. Clin. Pharmacol. 42 (1996) 291-300
12. Weber A.E., Mathvink R.J., Perkins L., Hutchins J.E., Candelore M.R., Tota L., Strander C.D., Wyvratt M.J., and Fisher M.H. Bioorg. Med. Chem. Lett. 8 (1998) 1101-1106
13. H. Michael, U.S. Patent 5,451,677, 1995.
14. Dale W.J., and Buell G. J. Org. Chem. 21 (1956) 45-48
15. Yardly J.P., and Fletcher III H. Synthesis 4 (1976) 244
16. K. Kojima, Eur. Patent 363,223, 1990.
17. Walsh D.A., Sancilio L.F., and Reese D.L. J. Med. Chem. 21 (1978) 582-585
18. +).